Saturday, November 21, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > CEO Life > Food > Baxter to divest biopharma solutions unit for $4.25 billion

Baxter to divest biopharma solutions unit for $4.25 billion

in Food, Health, News
5 questions facing the pharma industry in 2023
Share on LinkedinShare on WhatsApp

Baxter International Inc said on Monday a private-equity group, which includes Warburg Pincus and Advent International, has agreed to buy its biopharma solutions unit for $4.25 billion.

Medical device makers such as Baxter have been grappling with supply-chain shortages that began during the pandemic, while rising costs of raw materials, labor and transportation added more pressure.

Baxter announced its intent to explore alternatives for its biopharma solutions business and spin off its kidney care units in January, stating the restructuring will allow greater alignment with the company’s manufacturing footprint.

Reuters was first to report the private-equity consortium was in the lead to acquire Baxter’s biopharma solutions business.

Baxter will receive after-tax proceeds of $3.4 billion, which it intends to use to pay down the debt the company incurred when it purchased medical device maker Hill-Rom Holdings for $10.5 billion in 2021. Baxter had a market value of $19 billion and total debt of $16.6 billion, as of December 31.

Baxter estimates the transaction will reduce the company’s earnings by about $0.10 per share in the fourth quarter.

The medical device maker’s biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as vaccines.

Through the deal, Advent International and Warburg Pincus will gain access to Baxter BioPharma solutions’ manufacturing facilities and about 1,700 employees in Bloomington, Indiana and Halle, Germany.

Private-equity firms have increasingly been investing in the drug development sector, which was deemed as risky, by coming up with deals that compensate them for the uncertainty involved.

Through the deal with Baxter, which is expected to close in the second half of 2023, the private-equity firms hope to strengthen their presence in the contract drug manufacturing space.

By Khushi Mandowara and Bhanvi Satija / Reuters

Tags: biomedical engineeringBiotechPharmacueticalUnited States

Related Posts

U.S. Loses Measles-Free Status After 26 Years
Health

U.S. Loses Measles-Free Status After 26 Years

Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment
News

Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Bending Spoons acquires Mailchimp in $3.68 billion deal
News

Bending Spoons acquires Mailchimp in $3.68 billion deal

PayPal appoints HP’s Enrique Lores as CEO
News

PayPal names Claire Bramley as new CFO

Google selects Bezos’ Blue Origin for AI space project
News

Google selects Bezos’ Blue Origin for AI space project

Anthropic sets $1 trillion IPO valuation target
News

Anthropic raises more than $81 billion in record IPO

Walmart beats predictions in latest quarter
News

Walmart raises outlook, anticipating a busy holiday season

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia shares rally following earnings beat

Target aims for non-alcoholic cocktail market ahead of the holiday season
News

Target reports its strongest sales growth in five years

Huang joins top CEOs on Trump’s China trip
News

Trump arrives in China for historic Xi, Putin meeting

No Result
View All Result

Recent Posts

  • Why are we so obsessed with the ’90s?
  • U.S. Loses Measles-Free Status After 26 Years
  • Plane clapping – joyful or deeply cringe?
  • The 4 themes shaping new manufacturing
  • Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.